AAPL 206.655 1.0044% MSFT 384.86 2.7965% NVDA 106.185 3.3833% GOOGL 158.72 2.1693% GOOG 160.73 1.9084% AMZN 185.5673 2.7504% META 530.91 2.0451% AVGO 187.43 5.9465% BRK-A 795500.0 0.8495% BRK-B 530.135 0.6312% LLY 855.05 3.0901% TSLA 255.535 1.9123% TSM 163.78 3.783% V 336.305 0.5787% JPM 243.935 1.2683% UNH 426.3 -0.3879% NVO 62.61 2.137% WMT 95.78 0.8635% LVMUY 113.69 1.6632% XOM 108.77 1.3039%
Last update at 2025-04-24T16:53:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21
Wed 23 Apr 25, 10:12 PMIs Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
Wed 23 Apr 25, 05:02 PMAmerican Century Companies boosts stake in Biohaven, ETF Daily News says
Tue 01 Apr 25, 03:55 PMAvalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Wed 26 Mar 25, 11:00 AMBiohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025
Sun 09 Mar 25, 08:37 PMBiohaven price target lowered to $63 from $69 at Morgan Stanley
Fri 07 Mar 25, 03:31 PMEstimating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Wed 05 Mar 25, 10:57 AM| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -409.55100M | -569.84100M | -212.43000M | -118.66800M | -528.38600M |
| Minority interest | - | - | -1.81000M | - | - |
| Net income | -408.16800M | -570.27900M | -213.79600M | -118.66800M | -528.80500M |
| Selling general administrative | 56.90M | 130.86M | 37.41M | 16.05M | 134.45M |
| Selling and marketing expenses | 5.87M | - | - | - | - |
| Gross profit | -3.36900M | -1.38600M | 370.85M | -0.07200M | - |
| Reconciled depreciation | 6.91M | 1.39M | 1.39M | 0.07M | - |
| Ebit | -436.05100M | -464.18500M | -218.90000M | -114.50600M | -479.12200M |
| Ebitda | -429.13900M | -462.79900M | -217.50700M | -114.43400M | -479.12200M |
| Depreciation and amortization | 6.91M | 1.39M | 1.39M | 0.07M | 0.17M |
| Non operating income net other | - | - | -65.43500M | - | - |
| Operating income | -436.05100M | -567.93200M | -218.90000M | -114.50600M | -479.12200M |
| Other operating expenses | 436.05M | 567.93M | 218.90M | 114.51M | 479.12M |
| Interest expense | - | 1.39M | 41.55M | - | 12.71M |
| Tax provision | -1.38300M | 0.44M | 1.37M | 0.00000M | - |
| Interest income | - | - | - | - | - |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.38300M | 0.44M | 1.37M | -0.13430M | 0.42M |
| Total revenue | 0.00000M | 0.00000M | 462.51M | 0.00000M | - |
| Total operating expenses | 436.05M | 567.93M | 218.90M | 114.51M | 479.12M |
| Cost of revenue | 3.37M | 1.39M | 91.66M | 0.07M | - |
| Total other income expense net | 26.50M | -1.90900M | 6.47M | -4.16200M | -49.26400M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -408.16800M | -570.27900M | -848.39600M | -118.66800M | - |
| Net income applicable to common shares | - | -570.27900M | -846.58600M | -118.66800M | - |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 513.21M | 661.78M | 142.06M | 111.50M | 344.26M |
| Intangible assets | 18.40M | 18.40M | 18.40M | 39.09M | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 47.38M | 19.33M | 2.12M | 0.01000M | 11.55M |
| Total liab | 85.24M | 123.01M | 47.37M | 34.72M | 351.69M |
| Total stockholder equity | 427.98M | 538.77M | 34.69M | 16.78M | -7.42400M |
| Deferred long term liab | - | - | 13.11M | - | - |
| Other current liab | 36.54M | 79.32M | 37.16M | 27.12M | 52.10M |
| Common stock | 887.53M | 615.74M | 1676.79M | 1249.55M | 881.43M |
| Capital stock | 887.53M | 615.74M | - | - | - |
| Retained earnings | -499.29200M | -91.12400M | -2585.75500M | -1739.16900M | -972.37300M |
| Other liab | - | 2.41M | 2.64M | 1.91M | - |
| Good will | 1.39M | 1.39M | 1.39M | 0.00000M | - |
| Other assets | 0.00000M | 2.58M | 3.22M | 1.01M | - |
| Cash | 248.40M | 204.88M | 76.06M | 82.51M | 316.73M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 55.42M | 90.02M | 41.94M | 29.88M | 66.17M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -217.52500M | -174.29600M | 550.66M | 184.95M | -316.72700M |
| Short term debt | 3.31M | - | 62.50M | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 30.88M | 30.58M | 626.72M | 267.46M | - |
| Other stockholder equity | 39.80M | 13.87M | 169.66M | 98.94M | 83.52M |
| Property plant equipment | - | 52.14M | 14.69M | 13.56M | - |
| Total current assets | 442.45M | 586.97M | 94.82M | 89.76M | 328.28M |
| Long term investments | - | 0.00000M | 6.00M | 7.18M | - |
| Net tangible assets | - | 518.68M | -735.81800M | 16.78M | - |
| Short term investments | 133.42M | 260.46M | 192.65M | 223.19M | - |
| Net receivables | 13.65M | 46.14M | 9.91M | 120.11M | - |
| Long term debt | - | - | 626.72M | - | - |
| Inventory | -0.39600M | 56.16M | 6.73M | 39.56M | - |
| Accounts payable | 15.58M | 10.70M | 4.78M | 2.76M | 14.07M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | -3.62900M | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.06500M | 0.28M | -0.07300M | 0.31M | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 1676.79M | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -2585.75500M | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.40M | 2.58M | 3.22M | 1.01M | 7.83M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 70.77M | 74.81M | 47.24M | 21.74M | 15.98M |
| Capital lease obligations | 30.88M | 30.58M | - | - | - |
| Long term debt total | - | - | 626.72M | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -304.79000M | 28.27M | -2.69700M | - | - |
| Change to liabilities | 5.93M | 117.20M | 0.22M | - | - |
| Total cashflows from investing activities | -304.79000M | 26.55M | -2.69700M | - | - |
| Net borrowings | - | 420.44M | - | - | - |
| Total cash from financing activities | 767.60M | 138.45M | 152.24M | 434.59M | 340.46M |
| Change to operating activities | -34.53200M | 0.64M | 8.76M | - | - |
| Net income | -570.27900M | -213.79600M | -118.66800M | -528.80500M | -240.92200M |
| Change in cash | 165.55M | -6.44900M | 73.59M | 53.48M | 132.78M |
| Begin period cash flow | 77.06M | 83.51M | 9.92M | 264.25M | 131.47M |
| End period cash flow | 242.60M | 77.06M | 83.51M | 317.73M | 264.25M |
| Total cash from operating activities | -297.68900M | -145.84000M | -75.95700M | -377.33100M | -197.14100M |
| Issuance of capital stock | 283.80M | - | 0.00000M | - | - |
| Depreciation | 1.39M | 1.39M | 0.07M | - | - |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | -24.10200M | -37.96500M | - | - |
| Change to account receivables | - | -188.15800M | -120.11100M | - | - |
| Sale purchase of stock | - | 345.63M | - | - | - |
| Other cashflows from financing activities | 483.79M | 138.45M | 154.48M | 434.59M | 296.51M |
| Change to netincome | 299.81M | 128.66M | 33.66M | - | - |
| Capital expenditures | 41.07M | 0.94M | 2.70M | 2.53M | 4.17M |
| Change receivables | - | -188.15800M | - | - | - |
| Cash flows other operating | - | -41.24300M | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 40.30M | - | - | - |
| Change in working capital | -28.60400M | 1.66M | 8.98M | 3.32M | 5.39M |
| Stock based compensation | 193.56M | 65.64M | 29.50M | 54.97M | 16.93M |
| Other non cash items | 106.25M | 4.52M | 4.16M | 93.18M | 21.47M |
| Free cash flow | -338.76300M | -146.77800M | -78.65400M | -379.86500M | -201.30600M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| BHVN Biohaven Pharmaceutical Holding Co Ltd |
1.33 6.21% | 22.75 | - | - | - | 14.34 | -2.1877 | |
| NVO Novo Nordisk A/S |
1.31 2.14% | 62.61 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.30 2.09% | 63.55 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.42 0.29% | 491.00 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.92 0.50% | 590.76 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
215 Church Street, New Haven, CT, United States, 06510
| Name | Title | Year Born |
|---|---|---|
| Dr. Vladimir Coric M.D. | Chairman & CEO | 1971 |
| Mr. Matthew Buten | Chief Financial Officer | 1961 |
| Mr. George C. Clark | VP & Chief Accounting Officer | 1984 |
| Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer | 1961 |
| Ms. Jennifer Porcelli | VP of Investor Relations | NA |
| Mr. Warren Volles | Gen. Counsel & Chief Legal Officer | NA |
| Mr. Clifford Bechtold M.S. | Chief Compliance Officer | NA |
| Ms. Kimberly Gentile | Sr. VP of Clinical Operations | 1966 |
| Mr. John Tilton | Chief Commercial Officer of Rare Diseases | 1968 |
| Mr. Chris Barrett | Sr. VP of Commercial Strategy, Common Disease | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...